Drug Profile
WIN 65579
Alternative Names: SR 265579Latest Information Update: 08 Aug 2007
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Developer Chinoin; Sanofi Winthrop; Sanofi-Synthelabo
- Class Bronchodilators
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cardiovascular disorders